Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-Ab™
Target-Humanized Mouse Models (HUGO-GT™)
Target-Humanized Mouse Models (CDS)
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic
Obesity
MASH & MASLD
Cardiovascular
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
iCyagen
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Company Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeResource RepositoryAI-engineered AAV Capsid Enables Intravitreal Delivery for the Treatment of Diverse Retinal Degenerations
Poster

AI-engineered AAV Capsid Enables Intravitreal Delivery for the Treatment of Diverse Retinal Degenerations

AI-guided, iterative design–screen–validate capsid engineering (NGS-trained viability and retina-targeting models), followed by in vitro assays (HEK293T transduction, serum transduction-inhibition, heparin competition) and in vivo validation in mouse and cynomolgus monkey models via intravitreal delivery.
AI-engineered AAV Capsid Enables Intravitreal Delivery for  the Treatment of Diverse Retinal Degenerations

Overview

Retinal degenerations, including Leber’s congenital amaurosis type 1 (LCA1) and wet age-related macular degeneration (wAMD), represent leading causes of vision impairment and blindness, driven by a range of factors, including genetic mutations and pathological neovascularization. While adeno-associated viruses (AAVs) have emerged as a promising platform for sustained gene therapy, most AAVs typically require subretinal injections to reach target cells, which carry risks to retinal integrity. To overcome this limitation, we employed an AI-guided approach to AAV capsid engineering and developed AAV2.PN168, a novel AAV2-derived variant. AAV2.PN168 exhibits extensive retinal transduction via intravitreal injection in both non-human primates and mice. Furthermore, AAV2.PN168 demonstrates high therapeutic efficacy in mouse models of both LCA1 and wAMD. These findings suggest that AAV2.PN168 has translational potential in treating various retinal degenerations and other ocular diseases requiring efficient, wide-range retinal delivery of therapeutic agents.

Key Insights

A Cyagen/YIMA Gene conference poster presenting AAV2. PN168, an AI-engineered AAV2 capsid variant that achieves broad retinal transduction via intravitreal injection and shows therapeutic efficacy in mouse models of LCA1 and wet AMD.
  • AI-guided capsid engineering worked. NGS-trained models predicted capsid viability and retinal targeting with high accuracy (Spearman R ≈ 0.90 mouse, 0.895 NHP), and an iterative design–screen–validate loop over ~45–49 variants converged on AAV2.PN168.
  • Outperforms the current benchmark in both species. In cynomolgus monkeys, PN168 gave significantly higher GFP+ ONL cell ratios than AAV2.7m8 across macula, central, and peripheral retina; in mice it led on luminescence, fundus/section fluorescence, and eGFP mRNA versus AAV2.WT and 7m8.
  • Therapeutic proof-of-concept via the safer route. A single intravitreal dose restored ERG b-wave amplitudes in GucyDKO (LCA1) mice at 28 and 56 days, and PN168-anti-VEGFA produced durable recovery of subretinal exudation in hVEGFA-TG (wAMD) mice — suggesting an alternative to subretinal surgery and repeated anti-VEGF injections.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Download Details
Full Name
Email
Organization
Job Role
Country
Main Area of Research
Resource Preferences
Which type of solutions are you considering?
Do you plan to start a project with us within the next 6 months?
How did you hear about us?
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCompany OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research